By controlling the patient's blood sugar, small doses of chemotherapy are used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, and produce very strong anticancer effects without the cytotoxic effects of chemotherapy.
Male or female aged 18-75 years;
ASubjects must have histologically- or cytologically-confirmed diagnosis of advanced solid tumor(s) and have progressed on or is not eligible for available standard therapy;
Subjects have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (non-nodal lesions with longest diameter ≥ 10 mm, or nodal lesions with short diameter ≥ 15 mm);
ECOG score of 0-2, lifespan > 12 weeks;
The patient is diagnosed with central nervous system leukemia(symptoms, signs, imaging, cerebrospinal fluid);
White blood cell count ≥ 50×10^9/ L or patients with rapid disease progression can't be guaranteed to complete a full treatment cycle;
Patients with fungal, bacterial, viral or other uncontrollable infections or requiring four-level isolation treatment.
HIV, HBV and HCV positive;
Single group
Blood glucose stress combined with low-dose chemotherapy
Other interventionBy controlling the patient's blood sugar, low-dose chemotherapy is used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, produce very strong anticancer effects, and have no cytotoxic reactions to chemotherapy.
Relief degree of tumors
It will be evaluated by the Response Evaluation Criteria in Solid Tumors（RECIST1.1）
Progress free survival（PFS）
The duration from the beginning of treatment to cancer recurrence or progression
Overall survival（OS）
The duration from the beginning of treatment to patient death
Click on the lead sponsor to view all of their trials.
